Barbara Gayle Duncan - Feb 23, 2023 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Director
Signature
/s/ Danielle Mann for Barbara Duncan by PoA
Stock symbol
OVID
Transactions as of
Feb 23, 2023
Transactions value $
$0
Form type
4
Date filed
2/27/2023, 03:47 PM
Previous filing
Feb 6, 2023
Next filing
May 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +15K $0.00 15K Feb 23, 2023 Common Stock 15K $2.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date.